BIO-key International
BKYINASDAQUSD
- — Source valuation snapshot. Not a live recalculation.
- — Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- — Diluted earnings per share from the latest filed annual.
- $2.36 Prior regular-session close from the quote source.
- $2.45–$2.59 Regular-session low and high so far today.
- 448.7K Regular-session shares traded · Nov 11, 12:57 PM ET.
- Nov 13 projected Projected for 2026-11-13 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $1.55–$11.10 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own BKYI if its phone-free biometric IAM niche turns high gross margins into recurring growth before cash burn forces dilution.
BKYI price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
BIO-key’s Identity-Bound Biometrics remains relevant where phones and tokens are impractical, allowing PortalGuard to win as a specialized MFA layer for roving users, shared workstations and proxy-delegation-sensitive environments rather than needing to replace Microsoft, Okta, Ping or ForgeRock.HoldingMateriality: High
Item 1 says competing MFA solutions require a phone or token, while BIO-key makes the user, not the phone or token, the credential through Identity-Bound Biometrics. If this niche is real, BKYI can defend a focused revenue base; if it disappears, the company becomes a small undifferentiated IAM reseller competing with much larger platforms.
Watch: Microsoft Entra or Okta ships bundled phone-less biometric authentication for shared workstations that removes the need for BIO-key’s specialized layer.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 says competing MFA solutions require a phone or token, while BIO-key makes the user, not the phone or.
Open source ↗The business must remain software/IP-led, with fingerprint and FIDO hardware acting as accessories, so incremental sales carry software-like gross margins rather than becoming low-margin scanner resale or systems integration work.StrengtheningMateriality: High
MD&A says BIO-key sells biometric and FIDO hardware as accessories to its IAM platforms and does not mandate use of BIO-key hardware. High gross margins are the main evidence that BIO-key owns differentiated software value; losing that mix would make scale much harder and reduce any turnaround upside.
Watch: Large civil-ID or enterprise deals shift toward bundled third-party hardware and services where BIO-key captures mainly resale economics.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A says BIO-key sells biometric and FIDO hardware as accessories to its IAM platforms and does not mandate use of.
Open source ↗BIO-key’s annual subscription model and more than 85 channel partners must translate its niche differentiation into lower-cost recurring growth; if one-year contracts and reseller routes do not lower acquisition and support intensity, the company cannot self-fund.WeakeningMateriality: Medium
MD&A says the company operates a SaaS model with customers subscribing to term use of software for annual recurring revenue. This determines whether high gross profit can become operating cash flow for shareholders or remains trapped under fixed sales, R&D and support costs.
Watch: Resellers and system integrators prioritize Microsoft, Okta, Ping or other larger IAM vendors over BIO-key.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A says the company operates a SaaS model with customers subscribing to term use of software for annual recurring revenue.
Open source ↗WEB-key’s large-scale customer and civil-ID capability can create step-change opportunities if governments and regulated financial institutions keep choosing centralized fingerprint enrollment, de-duplication and authentication over device-bound or incumbent-integrator alternatives.HoldingMateriality: Medium
MD&A says one large bank has enrolled and identifies over 21.7 million customers using BIO-key fingerprint biometrics in branches daily. A single large regulated deployment could materially change BKYI’s revenue scale, but failure to win such projects leaves the company dependent on a small enterprise IAM base.
Watch: IDEMIA, Thales or NEC wins the large civil-ID tenders BIO-key targets.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A says one large bank has enrolled and identifies over 21.7 million customers using BIO-key fingerprint biometrics in branches daily.
Open source ↗Per-share value depends on funding the turnaround without punitive dilution; unless bookings accelerate or costs fall, external capital rather than customer economics will set shareholder outcomes.WeakeningMateriality: Medium
FY2025 cash was $2.69 million, up from $0.44 million at FY2024 year-end, giving the company more balance-sheet flexibility than the prior year. For a microcap with operating losses, survival can still come at a poor per-share return if new capital is raised on unfavorable terms.
Watch: A discounted equity or warrant financing transfers most turnaround value to new investors.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 cash was $2.69 million, up from $0.44 million at FY2024 year-end, giving the company more balance-sheet flexibility than the.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
BIO-key’s Identity-Bound Biometrics remains relevant where phones and tokens are impractical, allowing PortalGuard to win as a specialized MFA layer for roving users, shared workstations and proxy-delegation-sensitive environments rather than needing to replace Microsoft, Okta, Ping or ForgeRock. If this niche is real, BKYI can defend a focused revenue base; if it disappears, the company becomes a small undifferentiated IAM reseller competing with much larger platforms.
The business must remain software/IP-led, with fingerprint and FIDO hardware acting as accessories, so incremental sales carry software-like gross margins rather than becoming low-margin scanner resale or systems integration work. High gross margins are the main evidence that BIO-key owns differentiated software value; losing that mix would make scale much harder and reduce any turnaround upside.
BIO-key’s annual subscription model and more than 85 channel partners must translate its niche differentiation into lower-cost recurring growth; if one-year contracts and reseller routes do not lower acquisition and support intensity, the company cannot self-fund. This determines whether high gross profit can become operating cash flow for shareholders or remains trapped under fixed sales, R&D and support costs.
WEB-key’s large-scale customer and civil-ID capability can create step-change opportunities if governments and regulated financial institutions keep choosing centralized fingerprint enrollment, de-duplication and authentication over device-bound or incumbent-integrator alternatives. A single large regulated deployment could materially change BKYI’s revenue scale, but failure to win such projects leaves the company dependent on a small enterprise IAM base.
Per-share value depends on funding the turnaround without punitive dilution; unless bookings accelerate or costs fall, external capital rather than customer economics will set shareholder outcomes. For a microcap with operating losses, survival can still come at a poor per-share return if new capital is raised on unfavorable terms.
All standing thesis claims
Original report summary
its phone-free biometric IAM niche turns high gross margins into recurring growth before cash burn forces dilution.
BULL CASE / BEAR CASE
Bull case and bear case for Bio Key International
Where the evidence on Bio Key International disagrees: Mixed on the latest evidence (Nov 9, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.
Bull case: what the evidence supports
BIO-key’s Identity-Bound Biometrics remains relevant where phones and tokens are impractical, allowing PortalGuard to win as a specialized MFA layer for roving users, shared workstations and proxy-delegation-sensitive environments rather than needing to replace Microsoft, Okta, Ping or ForgeRock.
The business must remain software/IP-led, with fingerprint and FIDO hardware acting as accessories, so incremental sales carry software-like gross margins rather than becoming low-margin scanner resale or systems integration work.
WEB-key’s large-scale customer and civil-ID capability can create step-change opportunities if governments and regulated financial institutions keep choosing centralized fingerprint enrollment, de-duplication and authentication over device-bound or incumbent-integrator alternatives.
Bear case: what the evidence questions
BIO-key’s annual subscription model and more than 85 channel partners must translate its niche differentiation into lower-cost recurring growth; if one-year contracts and reseller routes do not lower acquisition and support intensity, the company cannot self-fund.
Per-share value depends on funding the turnaround without punitive dilution; unless bookings accelerate or costs fall, external capital rather than customer economics will set shareholder outcomes.
Thesis-Break Engine
Thesis-break watch · Bio Key International
No break has crossed Bio Key International’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MIXEDOther material event.
Bio Key International filed an SEC 8-K on 2026-10-06: Other material event. It is a dated development that tests the current thesis.
- MIXEDEntered a material definitive agreement.
Bio Key International filed an SEC 8-K on 2026-10-02: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MIXEDOther material event.
Bio Key International filed an SEC 8-K on 2026-09-08: Other material event. It is a dated development that tests the current thesis.
RISKS / FALSIFIERS
What could break the thesis
- Microsoft Entra or Okta ships bundled phone-less biometric authentication for shared workstations that removes the need for BIO-key’s specialized layer.
- Large civil-ID or enterprise deals shift toward bundled third-party hardware and services where BIO-key captures mainly resale economics.
- Resellers and system integrators prioritize Microsoft, Okta, Ping or other larger IAM vendors over BIO-key.
- IDEMIA, Thales or NEC wins the large civil-ID tenders BIO-key targets.
- A discounted equity or warrant financing transfers most turnaround value to new investors.
BKYI news
Loading headlines…
FINANCIAL STATEMENTS
BKYI income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
BKYI: quick answers
- When does Bio Key International (BKYI) report earnings next?
- Bio Key International's next results are projected for November 13, 2026, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on August 14, 2026. Earnings calendar
- What is BKYI's short interest?
- As of October 30, 2026, 270,717 BKYI shares were sold short, down 30.0% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. BKYI short interest history